RxSight, Inc.

Hello, and thank you for standing by. Welcome to the RxSite third quarter 2022 earnings conference call. At this time, all the participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you'll need to press star 11 on your telephone. You'll then hear an automated message advising you that your hand is raised. Please be advised that today's conference is being recorded. I'd like to now hand the conference over to your speaker today, Alex Wang, Associate Director of Investor Relations.

Thank you, Operator. Presenting today are President and Chief Executive Officer of RxSight, Ron Kurtz, and Chief Financial Officer, Shelley Toonan. Earlier today, RxSight released financial results for the three and nine months ended September 30, 2022. A copy of the press release is available on the company's website. Before we begin, I would like to inform you that comments and responses to questions during today's call reflect management's views as of today, November 7, 2022, and will include forward-looking and opinion statements including predictions, estimates, plans, expectations, and other information. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are more fully described in our press release issued earlier today and in our filings with the Securities and Exchange Commission, or SEC. Our SEC filings can be found on the company's or the SEC's website. Investors are cautioned not to place undue reliance on forward-looking statements, and we disclaim any obligation to update or revise these forward-looking statements. We will also discuss certain non-GAAP financial measures. Disclosures regarding these non-GAAP financial measures, including reconciliations with the most comparable GAAP measures, can be found in the press release. Please note that this conference call will also be available for audio replay on the company's website. With that, I will now turn the call over to President and CEO, Dr. Ron Kurtz.

Good afternoon and thank you for joining us. The RxSight team delivered record performance again this quarter, further demonstrating the significant advantages that our unique technology provides to both patients and doctors. Our financial and operational results continue to highlight the potential of the light adjustable lens to reshape and expand the premium IOL market, as the LAL is increasingly positioned by practices as the premium lens of choice for their patients. On today's call, Shelly is going to begin with a recap of the third quarter results and an overview of guidance for the fourth quarter, after which I'll provide some additional color.